Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXICET vs ALTABAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Management of moderate to severe pain where an opioid analgesic is appropriate
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Oxycodone is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6; acetaminophen is metabolized via conjugation (glucuronidation and sulfation) and by CYP2E1 (minor, but produces toxic NAPQI).
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Oxycodone: 45-50% (primarily albumin). Acetaminophen: 10-25% (minimal).
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
Oxycodone: 2.6 L/kg; large Vd indicates extensive tissue distribution.
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
Oral oxycodone: 60-87%; Acetaminophen: 75-85%.
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
e GFR 30-60 m L/min: reduce dose to 50-75% of usual. e GFR 10-29 m L/min: reduce dose to 25-50% of usual. e GFR <10 m L/min: avoid use or use with extreme caution; reduce dose to 25% and extend dosing interval to every 8-12 hours.
No dose adjustment required for renal impairment as systemic absorption is negligible.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce starting dose by 50% (e.g., oxycodone 2.5-5 mg) and monitor. Child-Pugh Class C: avoid use or use with extreme caution; reduce dose to 25% and extend interval.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
Weight-based: oxycodone 0.05-0.15 mg/kg per dose, acetaminophen 10-15 mg/kg per dose, orally every 4-6 hours as needed; maximum acetaminophen 75 mg/kg/day (not to exceed 4000 mg/day) in children ≥12 years; for children <12 years, max acetaminophen 75 mg/kg/day (max 325 mg per dose in children <6 years).
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
Start with lowest available dose (oxycodone 2.5-5 mg); consider extended dosing interval (every 6-8 hours); monitor renal and hepatic function; avoid in patients with advanced liver disease or GFR <30 m L/min.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity associated with acetaminophen.
No black box warnings.
Respiratory depression; increased intracranial pressure; severe hypotension; hepatotoxicity (acetaminophen); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; risks of use in patients with gastrointestinal obstruction; seizures; severe renal impairment.
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
Significant respiratory depression; acute or severe bronchial asthma; known hypersensitivity to oxycodone, acetaminophen, or any component; suspected or known gastrointestinal obstruction (e.g., paralytic ileus); severe hepatic impairment.
Hypersensitivity to retapamulin or any component of the formulation.
Avoid alcohol consumption as it increases the risk of hepatotoxicity from acetaminophen and enhances CNS depression from oxycodone. Grapefruit juice may potentiate oxycodone effects by inhibiting CYP3A4 metabolism; avoid concurrent use. High-fat meals may delay absorption of oxycodone but no specific food restrictions otherwise.
None known. Topical application with negligible systemic absorption; no dietary restrictions.
Pregnancy Category D (FDA). First trimester: Risk of neural tube defects and congenital anomalies with chronic use; no adequate studies. Second trimester: Continued risk of fetal dependence and withdrawal; growth restriction possible. Third trimester: High risk of neonatal opioid withdrawal syndrome (NOWS), respiratory depression, and preterm birth; avoid prolonged use.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
Oxycodone is excreted into breast milk; M/P ratio ~3.4 (for oxycodone). Relative infant dose 1.7-6.8% of maternal weight-adjusted dose; may cause infant sedation, respiratory depression, and withdrawal. Use with caution, monitor infant for somnolence and feeding difficulties; avoid if mother is on high doses or has CYP2D6 ultra-rapid metabolizer status.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
Increased hepatic clearance and volume of distribution in pregnancy may require dose adjustments. No specific guidelines; consider using lowest effective dose and short-term therapy. Taper if discontinuing to prevent withdrawal. Avoid in labor due to neonatal respiratory depression; reserve for severe pain.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
ROXICET contains oxycodone (an opioid agonist) and acetaminophen. Always assess pain severity and opioid tolerance before prescribing. Monitor for respiratory depression, especially in opioid-naive patients. The maximum daily acetaminophen dose is 4 g (consider hepatic impairment and alcohol use). Avoid concurrent use of other acetaminophen-containing products. Prescribe naloxone for patients at risk of overdose. Use with caution in elderly, renal impairment, and respiratory conditions.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Do not consume alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication.,Risk of dependence; do not share this medication with others. Store securely out of reach of children and pets.,Dispose of unused medication via a drug take-back program or mix with unpalatable substances and seal in a plastic bag before discarding.,Contact your doctor if you experience signs of allergic reaction (rash, itching, swelling), severe constipation, nausea/vomiting, or difficulty breathing.,Avoid taking other acetaminophen-containing products; do not exceed 4,000 mg of acetaminophen per day.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXICET vs ALTABAX, answered by our medical review team.
ROXICET is a Opioid Analgesic Combination that works by Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.. ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXICET and ALTABAX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXICET is: 1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).. The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXICET and ALTABAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXICET is classified as Category C. Pregnancy Category D (FDA). First trimester: Risk of neural tube defects and congenital anomalies with chronic use; no adequate studies. Second trimester: Continued risk of fetal d. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.